In focus · trending topic

Galectin-3 Inhibitor

2 stories · following the connections

Combination Immunotherapy of Pembrolizumab with the Galectin-3 Inhibitor GR-MD-02 Shows Promising Early Results in Treatment of Advanced Melanoma from a Phase 1b Clinical Trial

By Nasdaq OMXNov 13, 2017, 1:31 PM UTC

Combination Immunotherapy with Galectin-3 Inhibitor GR-MD-02 Enhances Effects in Pre-clinical Models and Early Results of Phase 1 Clinical Trials

By Nasdaq OMXFeb 7, 2017, 9:40 PM UTC